Rugby League player Carr banned for four years
16th December 2020,
Rugby league player Adam Carr has been banned from all sport for a period of four years following a first Anti-Doping Rule Violation (ADRV) for the presence of a banned substance in his Sample.
UK Anti-Doping (UKAD) collected an Out-of-Competition urine Sample from Mr Carr on 9 December 2019 at a Rochdale Hornets RLFC training session. Analysis of Mr Carr’s A Sample returned an Adverse Analytical Finding (AAF) for clenbuterol.
Clenbuterol is an anabolic agent used to gain muscle and burn fat. The drug is banned at all times under the WADA 2019 Prohibited List.
Speaking on the case, UKAD Director of Operations, Pat Myhill said: “This was a very serious matter that involved a powerful anabolic agent, purchased from a friend via a third party in a gym. Clenbuterol is not licensed for human consumption in the UK.
“Athletes at all levels who are playing in sports adhering to anti-doping rules are required to take full responsibility for what they ingest and use. Athletes should think very carefully about who or where they are getting any substances from. We strongly urge that all athletes speak to medical professionals or their governing body, and also take the time to personally research and review substances before taking them. Online resources are readily available on the UKAD website such as GlobalDRO and Informed Sport to support athletes when in doubt.”
On 28 February 2020, UKAD issued Mr Carr with a Notice of Charge and a Provisional Suspension. Mr Carr admitted that he had taken clenbuterol but challenged the imposition of any ban. The matter was therefore referred to the National Anti-Doping Panel (NADP) for determination. On 30 July 2020, the NADP issued Mr Carr with a four-year ban from sport, which started on 9 December 2019 and will expire at midnight on 8 December 2023.
Mr Carr subsequently appealed the NADP’s decision in his case. His appeal was ultimately dismissed on 3 December 2020 by an NADP appeal tribunal.
The original article can be found here.